Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

被引：0
作者：
Bei Wang
Rong Deng
Stefanie Hennig
Tanja Badovinac Crnjevic
Monika Kaewphluk
Matts Kågedal
Angelica L. Quartino
Sandhya Girish
Chunze Li
Whitney P. Kirschbrown
机构：
[1] Genentech,
[2] Inc.,undefined
[3] Certara,undefined
[4] Inc.,undefined
[5] F. Hoffmann-La Roche Ltd,undefined
[6] Clinical Pharmacology and Quantitative Pharmacology,undefined
[7] AstraZeneca,undefined
[8] Gilead Sciences,undefined
[9] Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 89卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：571 / 572
页数：1
相关论文
共 50 条
[31]   The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients [J].
Elisabetta Munzone ;
Alessandra Fabi ;
Giuseppe Buono ;
Roberta Caputo ;
Emilia Montagna ;
Mara Negri ;
Francesco Nuzzo ;
Antonella Palazzo ;
Ida Paris ;
Luca Conti ;
Anna Baggi ;
Jean Marie Franzini ;
Michelino De Laurentiis .
Drugs & Therapy Perspectives, 2023, 39 :432-446
[32]   Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer [J].
Whitney P. Kirschbrown ;
Bei Wang ;
Ihsan Nijem ;
Atsushi Ohtsu ;
Paulo M. Hoff ;
Manish A. Shah ;
Lin Shen ;
Yoon-Koo Kang ;
Maria Alsina ;
Sandhya Girish ;
Amit Garg .
Cancer Chemotherapy and Pharmacology, 2019, 84 :539-550
[33]   Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data [J].
Jagosky, Megan ;
Tan, Antoinette R. .
BREAST CANCER-TARGETS AND THERAPY, 2021, 13 :393-407
[34]   Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer [J].
Otoya, Iris ;
Valdiviezo, Natalia ;
Morante, Zaida ;
Calle, Cindy ;
Ferreyra, Yomali ;
Huarcaya-Chombo, Norma ;
Polo-Mendoza, Gabriela ;
Castaneda, Carlos ;
Vidaurre, Tatiana ;
Neciosup, Silvia P. ;
Calderon, Monica J. ;
Gomez, Henry L. .
INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
[35]   Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer [J].
Luo, Yang ;
Li, Wei ;
Jiang, Zefei ;
Zhang, Qingyuan ;
Wang, Liwei ;
Mao, Yixiang ;
Tjan-Heijnen, Vivianne C. G. ;
Im, Seock-Ah ;
McConnell, Robin ;
Bejarano, Sara ;
Fumagalli, Debora ;
Bines, Jose ;
Wang, Bei ;
Garg, Amit ;
Kirschbrown, Whitney P. ;
Xu, Binghe .
ANTI-CANCER DRUGS, 2019, 30 (08) :866-872
[36]   HOSPITAL CAPACITY TOOL TO ASSESS THE POTENTIAL IMPACT OF USING A FIXED DOSE COMBINATION OF PERTUZUMAB/TRASTUZUMAB FOR SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS PERTUZUMAB/ TRASTUZUMAB IN HER2+BREAST CANCER [J].
Cunha, A. .
VALUE IN HEALTH, 2023, 26 (12) :S296-S296
[37]   A Multicentre Study of Pathological Complete Response in HER2-positive Early Breast Cancer Treated with Neoadjuvant Pertuzumab and Trastuzumab [J].
Chambers, J. ;
Maxwell, A. ;
Kingdon, S. .
CLINICAL ONCOLOGY, 2019, 31 (07) :E106-E106
[38]   Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study [J].
O'Shaughnessy, J. ;
Sousa, S. P. ;
Cruz, J. ;
Fallowfield, L. J. ;
Auvinen, P. ;
Pulido, C. ;
Cvetanovic, A. ;
Wilks, S. ;
Ribeiro, L. ;
Burotto, M. ;
Klingbiel, D. ;
Messeri, D. ;
Alexandrou, A. ;
Trask, P. ;
Fredriksson, J. ;
Stamatovic, L. .
ANNALS OF ONCOLOGY, 2020, 31 :S42-S42
[39]   A BUDGET-IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER [J].
Walter, E. ;
Lazic-Peric, A. .
VALUE IN HEALTH, 2018, 21 :S26-S26
[40]   White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example [J].
Christian Jackisch ;
Federico Manevy ;
Suzanne Frank ;
Nicki Roberts ;
Jason Shafrin .
Advances in Therapy, 2022, 39 :833-844
12345